Insights
Insights From Our Experts
Articles
The Strategic Value of Medical & Scientific Fact-Checking in Medical, Legal and Regulatory Review
Posted by
Mary Mehrabian, PharmD, BCGP, BCMAS , Vaishnavi Gowda, MPhil, PhD , Michael DeLuca, PharmD, MBA, MSRA on January 14, 20261/14/26
In today’s highly regulated pharmaceutical industry, promotional and non-promotional materials must meet the highest standards of scientific accuracy, compliance, and trust. With growing scrutiny from regulators, healthcare professionals, and the public, fact-checking has become a strategic…
NAVLIN Daily 2025 Round-Up: The Pricing and Policy Trends Redefining Market Access
NAVLIN Daily by EVERSANA looks back at a year of rapid and often unpredictable global pricing and policy shifts that reshaped launch and access strategies worldwide. Throughout 2025, the NAVLIN Daily team supported the life sciences…
New Evidence Confirms Radiographic Progression-Free Survival (rPFS) as a Surrogate Endpoint for Overall Survival (OS) in Metastatic Castration-Resistant Prostate Cancer
Overall survival (OS) remains the gold standard in oncology trials, but waiting for long-term OS data can delay access to life‑prolonging therapies. Radiographic progression‑free survival (rPFS) has been increasingly used as a meaningful imaging-based primary endpoint…
No More Waiting: What the C-Suite Should Demand from an “AI Agency”
For C-suite leaders, the pressure to deliver speed, compliance and precision has never been greater, but most operating models are still built for a slower, manual era. Recent agency consolidations have exposed cracks in the system,…
A New Marketing Mandate in Community Oncology
As the next wave of oncology innovation—bispecific antibodies, ADCs, and CAR-T therapies—moves from academic centers into community practices, marketers face unprecedented clinical, operational, and financial hurdles. Success now demands a shift from traditional promotion to building…
How Pharma and PBMs Can Coexist and Lower Drug Costs Faster
The pharmaceutical industry and pharmacy benefit managers (PBMs) both play essential roles in getting medicines to patients. But years of complexity and competing incentives have strained the system. Our CEO Mark Thierer recently authored an article in Pharmaceutical Commerce, noting how meaningful progress will come not from…
Smarter, Faster, Compliant: Our Award-Winning Our AI-Powered Solutions Recognized in PM360’s Innovation Issue
In life sciences, speed and compliance aren’t optional, they’re mission-critical. Every delay in commercialization can cost millions, jeopardize launches, and ultimately impact patient access. At EVERSANA, we’ve reimagined the commercialization model with AI-powered solutions that deliver measurable impact: accelerating workflows, reducing costs,…
The Enablement Helix: An Evolving Framework for Market Success in Oncology
In today’s rapidly evolving oncology landscape, market success demands more than traditional promotional strategies – it requires a unified, cross-functional approach that empowers clinical partners and streamlines care delivery. EVERSANA’s dynamic framework, The Enablement Helix,…
Going Beyond Compliance: Transforming Aggregate Reports into Strategic Safety Intelligence
Posted on December 17, 202512/17/25
Leaders in today’s global pharmacovigilance (PV) teams are being pulled in two directions. On one side: the relentless demands of regulatory compliance. On the other hand, the growing need to act fast, make smarter decisions, and…
Digital-First Care and Affordability: Our Leaders Share Insights with pharmaphorum
Patients today expect care to be as seamless as buying online: on demand, transparent and personalized – pharma must adapt. Brian Laird, President, Patient Services, EVERSANA and Deanna Horner, SVP and Chief Pharmacy Officer, Waltz Health, explored how digital-first models, affordability…